The purpose of this page is to provide you with the most up-to-date information and guidance we have regarding COVID-19. Our goal is to consolidate relevant information and guidance for providers to help support our members.
For questions or more information, contact GCHP's Customer Service at 1.888.301.1228.
Centers for Disease Control and Prevention (CDC) 2024-2025 COVID-19 vaccination recommendation
Routine COVID-19 vaccination
- Children ages 6 months to 4 years
- Unvaccinated: Should receive a multidose initial series with a 2024–2025 mRNA vaccine.
- Previously completed an initial series: Should receive one dose of a 2024–2025 mRNA vaccine from the same manufacturer as the initial series.
- People ages 5 to 64 years: Should receive one dose of an age-appropriate 2024–2025 COVID-19 vaccine.
- People ages 65 years and older: Should receive two doses of any 2024–2025 COVID-19 vaccine, spaced six months (minimum interval two months) apart.
COVID-19 vaccination for people who are moderately or severely immunocompromised
- Unvaccinated: Should receive a multidose initial series with an age-appropriate 2024–2025 COVID-19 vaccine and one dose of a 2024–2025 COVID-19 vaccine six months (minimum interval two months) after completing the initial series.
- Previously completed an initial series: Should receive two doses of an age-appropriate 2024–2025 COVID-19 vaccine, spaced six months (minimum interval two months) apart.
- May receive additional age-appropriate 2024–2025 COVID-19 vaccine doses under shared clinical decision-making.
COVID-19 vaccine composition
The 2024–2025 formulations for COVID-19 vaccines approved or authorized in the United States have been updated to a monovalent vaccine based on the Omicron JN.1-lineage of SARS-CoV-2, as follows:
- Moderna and Pfizer-BioNTech: KP.2 strain
- Novavax: JN.1 strain
For additional COVID-19 vaccination information, please refer to the CDC COVID-19 Vaccination Clinical and Professional Resources.
COVID-19 vaccination and test sites
Safe, free, and effective COVID-19 vaccines are available to everyone 6 months of age and older. COVID-19 vaccines are offered at more than 200 sites in Ventura County by a network of medical offices, community clinics, pharmacies, public health clinics, and mobile clinics. Vaccine appointments may be made on MyTurn or by calling 1.833.422.4255 for scheduling support (available in multiple languages).
County of Ventura sponsored clinics
Ventura County Public Health operates COVID-19 vaccination clinics at the following locations for everyone 6 months of age and older. Appointments are encouraged, but not required. To make an appointment, visit MyTurn.ca.gov or call the California COVID-19 Hotline at 1.833.422.4255.
North Oxnard Public Health
2240 E. Gonzales Rd, Suite 140
Oxnard, CA 93036
1.805.981.5221
Hours: Monday, Tuesday, Thursday, and Friday - 8:30 a.m. to 4:30 p.m.; Wednesday - 8:30 a.m. to 6:30 p.m.
South Oxnard Public Health Clinic (C Street)
2500 S. C St., Suite B1
Oxnard CA, 93033
1.805.981.5221
Hours: Monday-Friday: 8:30 a.m. to 4:30 p.m.
Do your patients need transportation to a test or vaccination site?
Members can call Ventura Transit Systems at 1.855.628.7433 (TTY 711) to schedule a ride.
Outpatient COVID-19 pre-exposure prophylaxis and treatment options
Per the state Department of Health Care Services (DHCS) Medi-Cal Rx, the following are covered under the pharmacy benefit (when billed as a pharmacy claim):
- Paxlovid (nirmatrevir / ritonavir)
- New Dosing Regimen for Severe Renal Impairment (eGFR < 30 mL/min, including those who require hemodialysis)
- Day 1: Take 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) once.
- Days 2 through 5: Take 150 mg nirmatrelvir (one 150 mg tablet) with 100 mg ritonavir (one 100 mg tablet) once.
- On hemodialysis days, Paxlovid should be administered after hemodialysis.
- New Dosing Regimen for Severe Renal Impairment (eGFR < 30 mL/min, including those who require hemodialysis)
- Lagevrio (molnupiravir)
- Veklury (remdesivir)
- COVID-19 Vaccines
- At-home COVID-19 Antigen Test Kits (two kits, or four tests, per member per month)
For additional information, review the Medi-Cal Rx Provider Manual, Section 17.0: COVID-19 Vaccines, OTC Antigen Test Kits, and Therapeutics: Coverage and Reimbursements.
For more information, review the CDPH COVID-19 Treatment Resources for Healthcare Providers.
Gold Coast Health Plan’s 24-Hour Advice Nurse Line
To reach the 24-Hour Advice Nurse Line, call:
- 1.805.437.5001
- Toll-free: 1.877.431.1700
- If you use a TTY, call 711.
For more information, click here.
DHCS Medi-Cal Rx Bulletins & News
- May 1, 2025: Updates to the List of Contracted COVID-19 Antigen Tests, Effective June 1, 2025
- April 18, 2025: Updated COVID-19 Vaccine Reimbursement Rates
- Sept. 24, 2024: Pemgarda™ (pemivibart) Now a Medi-Cal Rx Benefit
- Sept. 1, 2024: COVID-19 Antigen Over-the-Counter Test Coverage Updates, Effective Oct. 1, 2024
- Jan. 17, 2024: Commercial Paxlovid (Nirmatrelvir/Ritonavir) for the Outpatient Treatment of COVID-19 covered Medi-Cal Rx Pharmacy Benefit
- Dec. 19, 2023: Commercial Lagevrio (Molnupiravir) for the Outpatient Treatment of COVID-19 covered Medi-Cal Rx Pharmacy Benefit
- Nov. 29, 2023: Commercial COVID-19 Vaccine Coverage for Children
- Oct. 1, 2023: COVID-19 Antigen Over-the-Counter Test Coverage Updates, Effective Nov. 1, 2023
- Sept. 22, 2023: Update: Reimbursement for New Commercial COVID-19 Vaccines
- Sept. 21, 2023: Reimbursement for New Commercial COVID-19 Vaccines
- Sept. 11, 2023: Coming Soon: Commercialization of COVID-19 Vaccines
- May 1, 2023: Discontinuation of the COVID-19 Uninsured Group Program
- May 1, 2023: Updates to the List of Covered Emergency Use of Authorization (EUA) COVID-19 Antigen Tests, Effective June 1, 2023
- March 1, 2023: Policy Update of Remdesivir (Veklury) for the Outpatient Treatment of COVID-19 as a Pharmacy Benefit
- Feb. 21, 2023: New Resources for Providers: COVID-19 Testing and Treatment Support
- Feb. 14, 2023: Evusheld® No Longer Authorized to Prevent COVID-19
- Feb. 1, 2023: Updates to Over-the-Counter (OTC) COVID-19 Antigen Test Kits, Effective March 1, 2023
- Dec. 30, 2022: Bebtelovimab No Longer Authorized to Treat COVID-19
- Dec. 9, 2022: COVID-19 Antigen Tests Coverage Reminder
- Oct. 21, 2022: Bivalent COVID-19 Vaccines Administration Now a Benefit
- Aug. 23, 2022: COVID-19 Vaccine Now a Benefit for Pediatric Population
Links and Resources
- California COVID-19 Vaccination Program
- California COVID-19 website
- COVID-19 Vaccine Timing
- CDPH COVID-19 Treatment Resources
- Food and Drug Administration (FDA) COVID-19 Vaccines
- Centers for Disease Control and Prevention (CDC) COVID-19
- COVID-19 Therapeutics Locator
- COVID-19 Therapeutics Myths and Facts
- DHCS Medi-Cal Rx Provider Manual
- Q&A: Treatment Information for Providers and Facilities
- Ventura County Public Health COVID-19 Information
Resources
- DHCS Telehealth Frequently Asked Questions
- March 7, 2023: Medi-Cal COVID-19 Public Health Emergency (PHE) Operational Unwinding Plan
- Jan. 30, 2023: Discontinuation of COVID-19 Emergency Fee-For-Service Medi-Cal Provider Enrollment
- Jan. 25, 2023: DHCS COVID-19 Vaccine Administration FAQs for Providers